PLx Pharma (FRA:1D5A) COGS-to-Revenue : 3.78 (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma COGS-to-Revenue?

PLx Pharma's Cost of Goods Sold for the three months ended in Sep. 2022 was €1.48 Mil. Its Revenue for the three months ended in Sep. 2022 was €0.39 Mil.

PLx Pharma's COGS to Revenue for the three months ended in Sep. 2022 was 3.78.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. PLx Pharma's Gross Margin % for the three months ended in Sep. 2022 was -278.21%.

PLx Pharma COGS-to-Revenue Historical Data

The historical data trend for PLx Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma COGS-to-Revenue Chart

PLx Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

COGS-to-Revenue

Get a 7-Day Free Trial

0.59

PLx Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
COGS-to-Revenue	Get a 7-Day Free Trial															0.59	0.56	0.56	1.70	3.78

PLx Pharma COGS-to-Revenue Calculation

PLx Pharma's COGS to Revenue for the fiscal year that ended in Dec. 2021 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.252	/	7.264
	=	0.59

PLx Pharma's COGS to Revenue for the quarter that ended in Sep. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.475	/	0.39
	=	3.78

PLx Pharma (FRA:1D5A) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

PLx Pharma's Gross Margin % for the three months ended in Sep. 2022 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.475 / 0.39
	=	-278.21 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

PLx Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of PLx Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma (FRA:1D5A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines